TRAX First Tracks Biotherapeutics, Inc. - Ordinary Shares
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$33.28
· of 52w range
· above low
· to high
$14.7252w low
$49.5852w high
Market Cap (MRQ)
$1.18B
your badges
52W Range
$15–$50
Analyst Rating
BUY
Price Target
$72
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
TRAX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$33.28
Market Cap (MRQ)
$1.18B
52W Range
$15–$50
TRAX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | TRAX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 7.0 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | TRAX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 14.3 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-92.2%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-0.95 | $-0.85 | -12.0% | |
| March 31, 2026 | $-1.45 | $-0.53 | -172.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $238M | |
| Prepaid Expense | $5M | |
| Other Current Assets | $2M | |
| Current Assets | $316M | |
| PP&E (Net) | $1M | |
| PP&E (Gross) | $9M | |
| Accum. Depreciation | $7M | |
| Other Non-current Assets | $256.0K | |
| Total Assets | $331M | |
| Accounts Payable | $3M | |
| Accrued Liabilities | $26M | |
| Current Liabilities | $31M | |
| Capital Leases | $12M | |
| Common Stock | $0 | |
| Retained Earnings | $0 | |
| AOCI | $-24.0K | |
| Stockholders' Equity | $287M | |
| Liabilities + Equity | $331M | |
| Shares Outstanding | 0 |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| R&D Expense | $26M | $34M | $39M | $41M | |
| SG&A Expense | $9M | $19M | $7M | $10M | |
| Operating Expenses | $35M | $53M | $46M | $51M | |
| Operating Income | $-35M | $-53M | $-46M | $-51M | |
| Other Non-op | $-1.0K | $-1.0K | $-13.0K | $-7.0K | |
| Net Income | $-33M | $-50M | $-42M | $-47M | |
| EPS (Basic) | $-0.95 | · | $-1.47 | · | |
| EPS (Diluted) | $-0.95 | · | $-1.47 | · | |
| Shares (Basic) | 35,003,000 | · | 28,810,000 | · | |
| Shares (Diluted) | 35,003,000 | · | 28,810,000 | · | |
| EBITDA | $-35M | $-53M | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $168M | $248M | · | · | |
| Prepaid Expense | $10M | $3M | · | · | |
| Other Current Assets | $2M | · | · | · | |
| Current Assets | $178M | $289M | · | · | |
| PP&E (Net) | $1M | $1M | · | · | |
| PP&E (Gross) | $8M | $8M | · | · | |
| Accum. Depreciation | $7M | $7M | · | · | |
| Other Non-current Assets | $0 | $0 | · | · | |
| Total Assets | $183M | $291M | · | · | |
| Accounts Payable | $3M | $7M | · | · | |
| Accrued Liabilities | $7M | $26M | · | · | |
| Current Liabilities | $12M | $33M | · | · | |
| Capital Leases | $2M | $0 | · | · | |
| Common Stock | $35.0K | · | · | · | |
| Retained Earnings | $-25M | · | · | · | |
| AOCI | $0 | $-146.0K | · | · | |
| Stockholders' Equity | $169M | $257M | · | · | |
| Liabilities + Equity | $183M | $291M | · | · | |
| Shares Outstanding | 35,390,679 | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $105.0K | $125.0K | $142.0K | $146.0K | |
| Stock-based Comp | $8M | $12M | $8M | $8M | |
| Other Non-cash | · | $6M | · | · | |
| Operating Cash Flow | $-32M | $-33M | $-39M | $-45M | |
| CapEx | $25.0K | $17.0K | $39.0K | $35.0K | |
| Investing Cash Flow | $-25.0K | $35M | $36M | $15M | |
| Financing Cash Flow | $-49M | $8M | $-52M | $6M | |
| Net Change in Cash | $-80M | $10M | $-54M | $-24M | |
| Free Cash Flow | · | $-33M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -36.4% | -34.8% | · | · | |
| ROE | -39.5% | -39.2% | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 14.3 | 8.7 | · | · | |
| Quick Ratio | 13.5 | 7.5 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | $4.77 | · | · | · | |
| Cash / Share | $4.75 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $712M | · | · | · | |
| P/B | 4.2 | · | · | · | |
| P / Tangible Book | 4.2 | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Company insiders 12 insiders · 4 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Daniel Faga | President, CEO | Aug. 15, 2026 A | · | 0 | 0 | $0 |
| Ajim Tamboli | Chief Financial Officer | May 12, 2026 A | · | 0 | 0 | $0 |
| Benjamin Stone | Chief Business Officer | Aug. 15, 2026 A | · | 0 | 0 | $0 |
| Lizzul Paul F. | Chief Medical Officer | Aug. 15, 2026 A | · | 0 | 0 | $0 |
| John A Orwin | Director | Sept. 15, 2026 M | 17,995 | 0 | 0 | $0 |
| Anthony J. Ware | Director | Sept. 2, 2026 M | 15,660 | 0 | 1 | $-1,758,287 |
| Rita Jain | Director | June 15, 2026 M | 19,194 | 0 | 0 | $0 |
| Magda Marquet | Director | June 15, 2026 M | 15,960 | 0 | 0 | $0 |
| John P. Schmid | Director | June 15, 2026 M | 37,652 | 0 | 0 | $0 |
| Dennis M Fenton | Director | June 15, 2026 M | 10,995 | 0 | 0 | $0 |
| EcoR1 Capital, LLC | 10% owner | April 20, 2026 S | 3,174,519 | 0 | 1 | $-64,983,991 |
| ANAPTYSBIO, INC | · | April 20, 2026 J | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 18 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.46% | 35,991 SH | Oct. 2, 2026 | Daily |
| IWC · iShares Trust | 0.21% | 79,376 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.08% | 2,520 SH | Oct. 2, 2026 | Daily |
| IWO · iShares Trust | 0.04% | 154,381 SH | Sept. 11, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 602,402 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 17,459 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 13,685 SH | Oct. 2, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 309,191 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 134,320 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 6,100 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 73,220 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 1,349 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 45,829 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 7,466 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,111,470 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,297 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 68,268 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 1,448 SH | Sept. 11, 2026 | Daily |
TRAX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 15 analysts
BUY
Median target
$65.00
+95.3%
5 33.3%
Strong Buy
9 60.0%
Buy
1 6.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
11 analysts · 2026-09-28Mean target $71.82 +115.8%
← Below all targets
Current price $33.28
Low$55.00
Mean$71.82
High$100.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| TRAX | · | · | · | · | · | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| AKTS | · | · | · | · | · | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026